VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,845,420 | +9.1% | 75,430 | +6.9% | 0.00% | 0.0% |
| Q2 2023 | $3,524,716 | +42.2% | 70,579 | +6.7% | 0.00% | 0.0% |
| Q1 2023 | $2,478,253 | +96.4% | 66,122 | +151.3% | 0.00% | – |
| Q4 2022 | $1,261,901 | +233.8% | 26,317 | +67.2% | 0.00% | – |
| Q3 2022 | $378,000 | +12.2% | 15,744 | +2.0% | 0.00% | – |
| Q2 2022 | $337,000 | +57.5% | 15,435 | +74.5% | 0.00% | – |
| Q1 2022 | $214,000 | +10.3% | 8,844 | +9.0% | 0.00% | – |
| Q4 2021 | $194,000 | -7.6% | 8,117 | -1.7% | 0.00% | – |
| Q3 2021 | $210,000 | +125.8% | 8,256 | +99.8% | 0.00% | – |
| Q2 2021 | $93,000 | +29.2% | 4,132 | +13.4% | 0.00% | – |
| Q1 2021 | $72,000 | +1.4% | 3,643 | +35.1% | 0.00% | – |
| Q4 2020 | $71,000 | -30.4% | 2,697 | +30.2% | 0.00% | – |
| Q3 2020 | $102,000 | – | 2,071 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $100,049,000 | 34.21% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $45,299,000 | 18.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 776,039 | $18,625,000 | 6.81% |
| Kynam Capital Management, LP | 698,638 | $16,767,000 | 3.53% |
| GREAT POINT PARTNERS LLC | 600,000 | $14,400,000 | 3.47% |
| Frazier Life Sciences Management, L.P. | 1,547,405 | $37,138,000 | 2.86% |
| Ghost Tree Capital, LLC | 360,000 | $8,640,000 | 2.42% |
| RA Capital Management | 4,581,203 | $109,949,000 | 2.35% |
| Opaleye Management Inc. | 190,000 | $4,560,000 | 1.88% |
| TPG GP A, LLC | 3,285,504 | $78,852,000 | 1.29% |